Coherus Oncology (CHRS) Competitors $0.72 -0.05 (-6.08%) Closing price 06/25/2025 04:00 PM EasternExtended Trading$0.75 +0.03 (+3.74%) As of 06/25/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. CYRX, AQST, PRTA, SNDL, MBX, HRTX, TERN, IVA, ATXS, and GOSSShould you be buying Coherus Oncology stock or one of its competitors? The main competitors of Coherus Oncology include CryoPort (CYRX), Aquestive Therapeutics (AQST), Prothena (PRTA), SNDL (SNDL), MBX Biosciences (MBX), Heron Therapeutics (HRTX), Terns Pharmaceuticals (TERN), Inventiva (IVA), Astria Therapeutics (ATXS), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Coherus Oncology vs. Its Competitors CryoPort Aquestive Therapeutics Prothena SNDL MBX Biosciences Heron Therapeutics Terns Pharmaceuticals Inventiva Astria Therapeutics Gossamer Bio Coherus Oncology (NASDAQ:CHRS) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation. Is CHRS or CYRX more profitable? CryoPort has a net margin of -50.15% compared to Coherus Oncology's net margin of -66.30%. Coherus Oncology's return on equity of 0.00% beat CryoPort's return on equity.Company Net Margins Return on Equity Return on Assets Coherus Oncology-66.30% N/A -26.51% CryoPort -50.15%-11.03%-5.54% Does the media favor CHRS or CYRX? In the previous week, CryoPort had 10 more articles in the media than Coherus Oncology. MarketBeat recorded 12 mentions for CryoPort and 2 mentions for Coherus Oncology. CryoPort's average media sentiment score of 0.27 beat Coherus Oncology's score of 0.00 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of CHRS or CYRX? 72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Comparatively, 10.0% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate CHRS or CYRX? Coherus Oncology presently has a consensus price target of $4.68, suggesting a potential upside of 549.56%. CryoPort has a consensus price target of $11.00, suggesting a potential upside of 54.06%. Given Coherus Oncology's higher probable upside, equities analysts clearly believe Coherus Oncology is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67CryoPort 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has more volatility and risk, CHRS or CYRX? Coherus Oncology has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Which has stronger earnings & valuation, CHRS or CYRX? Coherus Oncology has higher revenue and earnings than CryoPort. CryoPort is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus Oncology$266.96M0.31$28.51M-$1.13-0.64CryoPort$228.38M1.57-$114.76M-$2.34-3.05 SummaryCryoPort beats Coherus Oncology on 10 of the 16 factors compared between the two stocks. Get Coherus Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$89M$2.85B$5.42B$8.72BDividend YieldN/A2.69%5.37%4.21%P/E Ratio-0.6420.9825.0419.35Price / Sales0.31301.46405.63112.05Price / Cash2.6343.0735.9456.46Price / Book-0.637.338.005.50Net Income$28.51M-$55.19M$3.14B$248.18M7 Day Performance-6.07%1.09%0.86%0.75%1 Month Performance-4.64%8.30%5.13%4.44%1 Year Performance-56.57%0.64%39.07%16.85% Coherus Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus Oncology3.5653 of 5 stars$0.72-6.1%$4.68+549.6%-54.4%$89M$266.96M-0.64330CYRXCryoPort3.4785 of 5 stars$6.56+3.0%$11.00+67.7%-1.4%$328.92M$228.38M-2.801,186AQSTAquestive Therapeutics1.5126 of 5 stars$3.29+1.2%$10.14+208.3%+40.7%$326.80M$57.56M-5.58160News CoveragePRTAProthena3.67 of 5 stars$6.06+5.9%$31.50+419.8%-71.2%$326.21M$135.16M-2.91130Positive NewsGap UpHigh Trading VolumeSNDLSNDL3.8129 of 5 stars$1.24-0.8%$3.63+192.3%-33.7%$325.85M$671.81M-4.282,516Positive NewsMBXMBX Biosciences2.7406 of 5 stars$9.73-0.1%$37.50+285.4%N/A$325.22MN/A0.0036HRTXHeron Therapeutics4.1072 of 5 stars$2.11+5.5%$5.00+137.0%-29.5%$321.90M$144.29M-35.17300TERNTerns Pharmaceuticals4.3004 of 5 stars$3.68-5.6%$15.63+324.6%-44.0%$321.41MN/A-3.3840Positive NewsIVAInventiva1.8339 of 5 stars$3.34+1.5%$10.40+211.5%+0.3%$319.41M$9.95M0.00100ATXSAstria Therapeutics2.0572 of 5 stars$5.61-4.3%$30.00+434.8%-37.4%$316.57MN/A-3.0030GOSSGossamer Bio3.2958 of 5 stars$1.37-4.9%$7.75+465.7%+34.7%$311.40M$114.70M-5.96180Positive NewsGap Up Related Companies and Tools Related Companies CryoPort Alternatives Aquestive Therapeutics Alternatives Prothena Alternatives SNDL Alternatives MBX Biosciences Alternatives Heron Therapeutics Alternatives Terns Pharmaceuticals Alternatives Inventiva Alternatives Astria Therapeutics Alternatives Gossamer Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 6/26/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
